Dermatology

An analysis of the NIH's All of Us program finds no increased ILD risk with methotrexate in dermatomyositis.

In this review of dermatology news in April, we highlighted several major stories on such topics as cutaneous reactions to COVID-19, topical versus oral minoxidil, and FDA news.

A new study found a 2-week mindfulness-based intervention for patients with psoriasis does not improve skin status—it only helps the mind.

This observational cohort study looked at the link between obesity and eczema, highlighting regional differences in the skin disease and obesity’s interdependence.

This analysis highlighted several trends in search volume regarding eczema, including correlations with weather and climate.

The extent of stigma significantly differs based on disease visibility and severity among children with chronic skin disorders.

New phase 3b/4 trial data compared both drugs efficacy and safety profiles for eczema patients, looking at adults and adolescents.

A new study found intensive topical therapy improves deep sleep and REM sleep for patients with psoriasis and atopic dermatitis after 2 weeks.

Abeona's pz-cel is up for indicated use to treat patients with recessive dystrophic epidermolysis bullosa.

Eblasakimab shows promising itch relief in dupilumab-experienced atopic dermatitis patients, with significant reductions in symptoms observed.

This presentation at ACP Internal Medicine 2024 covered key skills Colven believes internists should know for identification of dermatologic conditions.

These data represent the largest single-center, long-term study on booster vaccines at a public hospital’s dermatology department in Japan.

This analysis compared the efficacy of a 5 mg daily dose of oral minoxidil to topical minoxidil, 5%, among male alopecia patients.

These data highlight the frequency of adverse events with narrow-band UVB phototherapy and concomitant therapy.

This analysis was conducted to address the fact that, while there are various acne specific instruments to assess quality of life domains, none exist to focus on all of the domains.

This study’s investigators point to the necessity of adapting an antibiotic stewardship program for acne treatment, with evaluation being done in dermatology practices to assess performance.

In these data, investigators had investigated the international differences in topical AK medication implementation, including links to countries’ different economic statuses.

TJ Chao and Kristine Kucera, PA’s go into dept of the recent developments in the systemic oral space of plaque psoriasis.

Physician assistants TJ Chao and Kristine Kucera discuss how the understanding of plaque psoriasis has changed over time and is now considered a systemic disease.

The FDA announcement on bimekizumab’s supplemental Biologics License Application followed the phase 3 BE HEARD I and II studies’ conclusion.

This analysis was conducted to evaluate the burden and disease characteristics of all 3 types of HAE among a set of Canadian patients.

In this review of the top stories in dermatology in March, several were highlighted such as the recent report on benzene in skincare products and the FDA’s approval of spesolimab for generalized pustular psoriasis.

Dermatologist and rheumatologist Saakshi Khattri highlights the importance of screening psoriasis patients for psoriatic arthritis and how that may impact treatment decisions.

Experts discuss the plethora of treatment options for psoriasis, including topicals, oral therapies, phototherapy, and biologics.

Dermatology physician assistants are talking about the evolving role of their profession in taking care of patients with plaque psoriasis.

Advances practice providers TJ Chao, MPAS, PA-C and Kristine Kucera, PA-C, MPAS, DHS discuss the recent development in the treatment landscape of plaque psoriasis.

Following this analysis, the conclusions provide more information on the views of potential dermatology patients on the future of their own medical images by artificial intelligence systems.

An expert in dermatology provides insight on approaching treatment in patients with plaque psoriasis who have a low BSA involvement, but with symptoms that present in difficult-to-treat areas.

Dr April W. Armstrong comments on patient selection for oral systemic treatments for plaque psoriasis management.

The FDA identified high concentration of lidocaine across marketed, over-the-counter topical products from 6 different companies.